Institute for Molecular Bioscience, University of Queensland, St. Lucia, Queensland, Australia.
Clem Jones Centre for Ageing Dementia Research, Queensland Brain Institute, University of Queensland, Brisbane, Queensland, Australia.
Epilepsia. 2023 Dec;64(12):3377-3388. doi: 10.1111/epi.17776. Epub 2023 Oct 17.
N-methyl-d-aspartate (NMDA) receptors are expressed at synaptic sites, where they mediate fast excitatory neurotransmission. NMDA receptors are critical to brain development and cognitive function. Natural variants to the GRIN1 gene, which encodes the obligatory GluN1 subunit of the NMDA receptor, are associated with severe neurological disorders that include epilepsy, intellectual disability, and developmental delay. Here, we investigated the pathogenicity of three missense variants to the GRIN1 gene, p. Ile148Val (GluN1-3b[I481V]), p.Ala666Ser (GluN1-3b[A666S]), and p.Tyr668His (GluN1-3b[Y668H]).
Wild-type and variant-containing NMDA receptors were expressed in HEK293 cells and primary hippocampal neurons. Patch-clamp electrophysiology and pharmacology were used to profile the functional properties of the receptors. Receptor surface expression was evaluated using fluorescently tagged receptors and microscopy.
Our data demonstrate that the GluN1(I481V) variant is inhibited by the open pore blockers ketamine and memantine with reduce potency but otherwise has little effect on receptor function. By contrast, the other two variants exhibit gain-of-function molecular phenotypes. Glycine sensitivity was enhanced in receptors containing the GluN1(A666S) variant and the potency of pore block by memantine and ketamine was reduced, whereas that for MK-801 was increased. The most pronounced functional deficits, however, were found in receptors containing the GluN1(Y668H) variant. GluN1(Y668H)/2A receptors showed impaired surface expression, were more sensitive to glycine and glutamate by an order of magnitude, and exhibited impaired block by extracellular magnesium ions, memantine, ketamine, and MK-801. These variant receptors were also activated by either glutamate or glycine alone. Single-receptor recordings revealed that this receptor variant opened to several conductance levels and activated more frequently than wild-type GluN1/2A receptors.
Our study reveals a critical functional locus of the receptor (GluN1[Y668]) that couples receptor gating to ion channel conductance, which when mutated may be associated with neurological disorder.
N-甲基-D-天冬氨酸(NMDA)受体在突触部位表达,在那里它们介导快速兴奋性神经传递。NMDA 受体对大脑发育和认知功能至关重要。编码 NMDA 受体必需 GluN1 亚基的 GRIN1 基因的自然变体与包括癫痫、智力障碍和发育迟缓在内的严重神经疾病有关。在这里,我们研究了三个错义变体对 GRIN1 基因的致病性,p.Ile148Val(GluN1-3b[I481V])、p.Ala666Ser(GluN1-3b[A666S])和 p.Tyr668His(GluN1-3b[Y668H])。
在 HEK293 细胞和原代海马神经元中表达野生型和含变体的 NMDA 受体。使用膜片钳电生理学和药理学来分析受体的功能特性。使用荧光标记的受体和显微镜评估受体表面表达。
我们的数据表明,GluN1(I481V)变体被开放孔阻滞剂氯胺酮和美金刚抑制,其效力降低,但对受体功能影响不大。相比之下,其他两个变体表现出功能获得的分子表型。含有 GluN1(A666S)变体的受体对甘氨酸的敏感性增强,并且孔阻滞剂美金刚和氯胺酮的效力降低,而 MK-801 的效力增加。然而,最明显的功能缺陷是在含有 GluN1(Y668H)变体的受体中发现的。GluN1(Y668H)/2A 受体表现出表面表达受损,对甘氨酸和谷氨酸的敏感性提高了一个数量级,并且对细胞外镁离子、美金刚、氯胺酮和 MK-801 的阻断作用受损。这些变体受体也可以被谷氨酸或甘氨酸单独激活。单受体记录显示,这种受体变体打开到几个电导水平,并比野生型 GluN1/2A 受体更频繁地激活。
我们的研究揭示了受体(GluN1[Y668])的一个关键功能位点,该位点将受体门控与离子通道电导偶联,当该位点发生突变时,可能与神经疾病有关。